GAPDHP23

Across TCGA pan-cancer cohorts, GAPDHP23 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of GAPDHP23’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GAPDHP23 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP23 is over-expressed in tumor, although a few such as KIRP and PAAD show the opposite, repressed pattern.

HNSC, KIRP, and PAAD are the cancer types where GAPDHP23 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP23 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.057	.009	4	view →
KIRP	Male	All	−0.053	.019	3	view →
PAAD	Female	All	−0.215	.048	2	view →
CHOL	All	All	−0.214	.005	2	view →
KICH	All	All	−0.076	.006	2	view →
KIRC	All	III,IV	+0.058	.017	2	view →
LUAD	Female	All	−0.043	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

GAPDHP23–HNSC

Open the HNSC breakdown →